Acknowledgements relating to this article

Assistance with the letter: none.

Financial support and sponsorship: none.

Conflicts of interest: none.

References

1 Feldheiser A, Gelman S, Chew M, et al. Vasopressor effects on venous return in septic patients: a review. *Eur J Anaesthesiol* 2021; 38:659–663.
2 Brengelmann GL. Venous return and the physical connection between distribution of segmental pressures and volumes. *Am J Physiol Heart Circ Physiol* 2019; 317:H939–H953.
3 Kamal Shafii SM, Contantino C, Chilari F, et al. Function of arteries and veins in conditions of simulated cardiac arrest. *Biomech Impacts* 2021; 11:157–164.
4 Gelman S. What drives venous return? *Eur J Anaesthesiol* 2022; 39:196–197.
5 Guaraccino F, Bertini P, Pinsky MR. Cardiovascular determinants of resuscitation from sepsis and septic shock. *Crit Care* 2019; 23:118.
6 Hesmay M, Jansen JR, Versprille A. Effects of endotoxin infusion on mean systemic filling pressure and flow resistance to venous return. *Pflugers Arch* 1996; 431:741–747.
7 Cecconi M, Auo HD, Geisen M, et al. Changes in the mean systemic filling pressure during a fluid challenge in postsurgical intensive care patients. *Intensive Care Med* 2013; 39:1299–1305.

DOI:10.1097/EJA.0000000000001661

OPEN

Intravenous fluids: issues warranting concern

Friedrich Mertzlufft, Franz Brettner, George J. Crystal, Markus W. Hollmann, Anton Kasatkin, Per-Arne Lönngqvist, Dominique Singer, Robert Sümpe1mann, Volker Wenzel, Rolf Zander and Thomas Ziegenfuß

From the v. Bodenischwqg Foundation Bethel, University Hospital Bielefeld, Bielefeld University (FM), Department of Anaesthesiology and Intensive Care Medicine, Hospital Barnherzige Brauder, Munich, Germany (FB), Department of Anaesthesiology, University of Illinois College of Medicine, Chicago, Illinois, USA (GJ-C), Department of Anaesthesiology, Amsterdam UMC, location AMC, Amsterdam, Netherlands (MW-H), Department of Anaesthesiology and Intensive Care, Clinical Hospital 9; Ijevsk, Russia (AK), Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden (PA-L), Division of Neonatology and Paediatric Critical Care Medicine, University Medical Center Eppendorf, Hamburg, Germany (DS), Clinic of Anaesthesiology, Hannover Medical School, Hannover, Germany (RS), Department of Anaesthesiology, Friedrichshafen Regional Medical Center, Friedrichshafen, Germany (VW), Physioklin, Mainz (RZ) and Department of Anaesthesiology and Intensive Care Medicine, St. Josef Hospital, Moers, Germany (TZ)

Correspondence to Friedrich Mertzlufft, Prof. Dr., v. Bodenischwqg Foundation Bethel, University Hospital Bielefeld, Campus Bielefeld-Bethel, Bielefeld University, Maraweg 21, D-33611 Bielefeld, Germany
Tel: +49 521 772 79010; fax: +49 521 772 79011;
e-mail: Fritz.Mertzlufft@evkb.de

Editor,

We are making a clarion call for the development and availability of intravenous fluids that have a physiological composition and complete and transparent labeling. Intravenous administrations of fluid are used in peri-operative medicine to maintain homeostasis and to restore normal physiology in a wide variety of clinical scenarios. These scenarios include their routine use during anaesthesia and surgery in adults and children, and in the treatment of the critically ill suffering from a variety of pathologies. The physiological end-points targeted by the infusions include systemic blood volume, and in turn, cardiac output, tissue perfusion, metabolic function, electrolyte concentrations and acid–base balance. Although colloids have the advantage of remaining predominantly intravascular, they may cause haemostasis and renal dysfunction. As a result, crystalloids that are free of these risks and much less expensive than colloid solutions, are currently used in nearly all situations.

Crystalloid solutions vary widely in chemical composition, affecting their efficacy and ability to cause adverse effects, including those related to volume loading and electrolyte imbalance. Their side effects may have serious consequences both in adults and children especially when the infusion volume is large and given over a long duration. The solutions used for intravenous infusions contain biologically active chemicals and so are categorised as drug products by local agencies, such as the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA). However, despite this designation, fluid physiology receives little attention in medical education and in the medical and scientific literature. This problem is exacerbated by packaging of the solutions that lacks information about chemical composition, such as osmolality and potential base excess (BE$_{pot}$), dose, indications, contraindications and potential side-effects. This absence of transparency has prompted wide-spread frustration among clinicians, as reflected in the international nature of the contributing authors above. We recommend that labeling of the various crystalloidal formulations be updated to reflect their physiological consequences, and that the protocols related to the infusion of these fluids be more widely taught, standardised and evidence-based.

The scientific evidence guiding fluid choice and dosing is limited. Indeed, the current guidelines are based on physiological experiments performed in the laboratory rather than comparative clinical trials. Although this lack of reliable clinical data was first recognised by researchers in Europe in the early 2000s, little progress has been made since then. In 2018, Boer et al. emphasised this shortcoming in their review article in the *British Journal of Anaesthesia*. The current interest and wide international reach of the controversy related to intravenous fluid choice is evident from discussion in three articles from Europe and the United States published in 2020 and 2021.

The rationale for new guidelines governing the use of an intravenous fluid should be based on its ability to maintain or restore the body’s internal environment, the so-called
'milieu interieur'. Normally this condition is maintained by intrinsic physiological mechanisms and is exemplified by a remarkable constancy for osmotic activity and buffer base concentration in blood plasma within and between individuals. A review of values \(^2-10\) demonstrates that osmolality varies by only 1.5% \(^7,28\) (288 mosmol kg\(^{-1}\) H\(_2\)O\(^{-1}\), weighted mean value \(n = 263\)) and buffer bases (48 mmol l\(^{-1}\)), expressed as base excess, vary by only 2.2% \(^0,10\) (BE \(\pm\) 0 mmol l\(^{-1}\), weighted mean value \(n = 90\)).

The crystalloid fluids best suited to maintain an extracellular fluid (ECF) composition within stringent physiological limits are homogeneous, and iso-tonic (osmolality), iso-hydric (base excess) and iso-ionic (sodium, potassium, chloride), not only in vitro but also in the patient after metabolism of the ingredients. \(^1,7\) Achieving wide spread implementation of this approach will require that standard definitions for osmolality and potential base excess (BE\(_{pot}\)) be adopted.

Osmolality is a measure of solute concentration as defined as the number of osmotically active particles per kilogram water. It is critical that the infused crystalloids have the same osmolality – not osmolarity – as fluids within the body, such as blood plasma. Plasma osmolality can be measured directly using freezing point depression or, as is done routinely in clinical practice, calculated from osmolality by summing up the active constituents per litre of water (such as sodium, chloride, glucose) and applying the appropriate correction factors. \(^8\) By pure chance, the actual osmolality of plasma (288 mosmol kg\(^{-1}\) H\(_2\)O\(^{-1}\)) is virtually identical to the theoretical osmolality of 291 mosmol l\(^{-1}\) calculated from its chemical composition, not ‘308 mOsm l\(^{-1}\)’, according to the American Academy of Pediatrics. \(^12\) This coincidence is a probable cause for confusion regarding the use of the terms osmolality and osmolarity.

The following examples demonstrate how the corresponding values for osmolality and osmolarity of various solutions can vary, sometimes substantially. \(^11\)

1. 0.9% saline has a theoretical osmolality of 308 mosmol l\(^{-1}\) (=154 mmol l\(^{-1}\) Na\(^+\) + 154 mmol l\(^{-1}\) Cl\(^-\)) but an actual osmolality of 286 mosmol kg\(^{-1}\) H\(_2\)O\(^{-1}\). This disparity is because some of the infused electrolytes are not osmotically effective.

2. Lactated Ringer’s (Hartmann’s) solution is hypotonic relative to plasma (an osmolality of 276 instead of 308 mosmol l\(^{-1}\)) and an osmolality of 256 instead of 288 mosmol kg\(^{-1}\) H\(_2\)O\(^{-1}\).

3. Glucose (Dextrose) 5% has a theoretical osmolality of 278 mosmol l\(^{-1}\), an in vitro osmolality of 290 mosmol kg\(^{-1}\) H\(_2\)O\(^{-1}\) (isotonic), but, because of metabolic breakdown of glucose, an in vivo osmolality of 0 mosmol kg\(^{-1}\) H\(_2\)O\(^{-1}\), which is equivalent to pure water. Simple calculations demonstrate that an infusion of 21 of this glucose solution in an adult can have a profound impact on osmolality of the various fluid compartments in the body. The immediate increase in ECF volume from 15 to 171 caused by such an infusion would be accompanied by a decrease in plasma osmolality from 288 to 254 mosmol kg\(^{-1}\) H\(_2\)O\(^{-1}\). However, the excess water diffuses rapidly into the intracelluar fluid (ICF) of 301, thus decreasing osmolality to 276 mosmol kg\(^{-1}\) H\(_2\)O\(^{-1}\) in the 451 whole body compartment. The 21 of water are eventually excreted by the kidney.

It is evident that a standardisation of units (osmolality vs. osmolarity) and clear labeling is necessary to avoid inappropriate use of fluids that could lead to iatrogenic hypo-osmolality and subsequent encephalopathy. We recommend that a warning label be added to glucose solutions indicating that osmolality of the combined ECF and ICF compartment could become negative after a 2 l infusion. The EMA recently issued such a warning. \(^13\) Notably, the Pharmacovigilance Risk Assessment Committee (PRAC) has recommended that special warnings and precautions be included in the Summaries of Product Characteristics for glucose-containing electrolyte solutions. \(^13\)

BE\(_{pot}\) (in mmol l\(^{-1}\)) is a useful index for predicting the influence of an infused solution on the acid–base equilibrium. BE\(_{pot}\) indicates the amount of bicarbonate that can potentially be consumed or released in the body after infusion of a fluid. It is currently recommended for inclusion on labeling of solutions by manufacturers in Europe, especially in Germany and Austria. \(^11\) The following example uses BE\(_{pot}\) to explain how crystalloid solutions can differ markedly in their effect on acid–base balance. An infusion of saline 0.9%, which lacks the bicarbonate concentration present in plasma (24 mmol l\(^{-1}\)), has an acidifying effect (BE\(_{pot}\) = 24 mmol l\(^{-1}\)), and thus may cause hyperchloreaemic acidosis. In contrast, an ‘acetate-buffered’ crystalloid solution containing 45 mmol l\(^{-1}\) of acetate has a BE\(_{pot}\) of +21 mmol l\(^{-1}\) (acetate 45 minus bicarbonate 24 mmol l\(^{-1}\)) and is, therefore, an alkalisating solution. Acetate is rapidly metabolised in muscle and other tissues leading to an indirect release of equimolar amounts of bicarbonate. Because of its alkalisating influence as well as for other reasons, \(^11\) we prefer acetate over lactate solutions for infusions. Furthermore, we recommend that the label ‘buffered’ \(^14\) or ‘acetate-buffered’ \(^14\) for infusion solutions should be replaced by either ‘acetate-containing’ or ‘physiologically composed balanced isotonic’ solution, as acetate per se has no inherent buffering capability. \(^11\)
In conclusion, we recommend strongly that the medical community take Lönqvist’s appeal (‘time for a solution’) seriously, and urge medical companies and manufacturers to provide improved infusion solutions that are physiologically composed and balanced (Table 1), and which include clear and detailed guidance for their safe and effective use. We believe that these relatively simple steps, which can be achieved without increasing costs, will have a substantial clinical benefit in reducing morbidity and potentially saving lives.

Acknowledgements relating to this article
Assistance with the letter: none.

Financial support and sponsorship: support was provided solely from institutional and departmental sources.

Conflicts of interest: none.

References
1. Lönqvist PA. Inappropriate perioperative fluid management in children: time for a solution? Paediatr Anaesth 2007; 17:203–205.
2. Boer C, Bosser SM, Koning NJ. Choice of fluid type: physiological concepts and perioperative indications. Br J Anaesth 2018; 120:384–396.
3. Maheshwari K, Turan A, Makarova N, et al. Saline versus lactated Ringer’s solution: the Saline or Lactated Ringer’s (SOLAR) Trial. Anesthesiology 2020; 132:614–624.
4. Story DA. Intravenous fluids: which recipe? Anesthesiology 2020; 132:609–611.
5. Kasatkin A, Unakov A, Nigmatullina A, et al. Balanced Crystalloid versus 0.9% sodium chloride: what we overlook in our research. Anesthesiology 2021; 134:353–354.
6. Zander R. Fluid management – second expanded (corrected) edition 2020. Paperback, ISBN: 978-3-347-12851-4.
7. Fazekas AS, Funk GC, Klobassa DS, et al. Evaluation of 36 formulas for calculating plasma osmolality. Intensive Care Med 2013; 39:302–308.
8. Lentner C. Physical chemistry, blood, somatometric data. In: Lentner C, editor. Geigy scientific tables, vol. 3. Basle: Ciba-Geigy Limited; 1984. p. 73; ISBN: 0914168525 9780914168522.
9. Zander R. Lang W. Letter to the editor: base excess and strong ion difference: clinical limitations related to inaccuracy. Anesthesiology 2004; 100:459–460.
10. Zander R. Lang W. Letter to the editor: base excess and strong ion difference: clinical limitations related to inaccuracy. Anesthesiology 2004; 100:459–460.
11. Sumpelmann R, Becke K, Zander R, et al. Perioperative fluid management in children: can we sum it all up now? Curr Opin Anaesthesiol 2019; 32:384–391.
12. Feld LG, Neuspiel DR, Foster BA, et al., SUBCOMMITTEE ON FLUID AND ELECTROLYTE THERAPY. Clinical Practice Guideline: maintenance intravenous fluids in children. Pediatrics 2018; 142:e20183083.
13. European Medicines Agency (EMA): Annual Report 2017. Available at: https://www.ema.europa.eu/en/news/ema-2017-annual-report-published.
14. Potura E, Lindner G, Biesenbach P, et al. An acetate-buffered balanced crystalloid versus 0.9% saline in patients with end-stage renal disease undergoing cadaveric renal transplantation: a prospective randomized controlled trial. Anesth Analg 2015; 120:129–129.

DOI:10.1097/EJA.0000000000001568

Intravenous lidocaine and cancer outcomes after radical cystectomy
Laure Cazenave, Marion Faucher, Maxime Tourret, Mathieu Marques, Marie Tezier and Djamel Mokart

From the Service d’Anesthésie-Réanimation, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon (LC) and Service d’Anesthésie-Réanimation, Institut Paoli-Calmettes, Marseille Cedex, France (IM, MT, MM, MT, DM)

Correspondence to Djamel Mokart, MD, PhD, Département d’Anesthésie et de Réanimation, Institut Paoli-Calmettes, 232 Bd Sainte Marguerite 13009, Marseille Cedex 09, France
Tel: +33 491223521; fax: +33 491223556; e-mail: mokartd@ipc.unicancer.fr

Editor,

Radical cystectomy is a major operation associated with high morbidity. The peri-operative period may be associated with an increased risk of cancer recurrence. As anaesthesia is a key element of the peri-operative period, numerous studies have shown a potential outcome benefit on immunomodulation of different analgesic techniques and drugs. Intravenous lidocaine could present potential antitumour effects likely to modulate the peri-operative inflammatory response. We investigated the association between intra-operative intravenous lidocaine and overall survival (OS) and disease-free survival (DFS). We hypothesised that use of lidocaine is an independent predictor of improved OS in patients undergoing radical cystectomy for bladder cancer. We conducted a retrospective observational study in a cancer referral centre in France (Institut Paoli-Calmettes, Marseille). All patients undergoing an elective radical cystectomy for bladder cancer from 1 July 2014 to 30 September 2019 at Institut Paoli-Calmettes, Marseille were included in the study. Data were collected until June 2020. Exclusion criteria were partial cystectomy, all re-interventions after partial cystectomy and radical cystectomy performed for locally advanced gynaecological cancer. Ethical approval of this study (Ethical reference: CYST-IRAAC-IPC 2019-047) was provided by the Institutional Review Board of the Institut Paoli-Calmettes, Marseille, France, on 11 November 2019.

In all patients, induction of general anaesthesia (GAB) was standardised and modalities of general anaesthesia and analgesia are described, according to the implementation of the urological Enhanced Recovery After Surgery (ERAS) protocols (before = period 1, after = period 2), in Supplemental Material 1, http://links.lww.com/EJA/A587. Thus,